RESUMEN
BACKGROUND: Postural orthostatic tachycardia syndrome (POTS) is a rare disease that is believed to be mediated by dysautonomia. Gastrointestinal complaints in POTS patients are common and disturbing but not well characterized. AIMS: We hypothesized that gastrointestinal dysmotility may be contributory to these symptoms. METHODS: We studied 12 POTS patients who presented with gastrointestinal symptoms to a tertiary referral center. Gastrointestinal symptoms were quantified using a previously validated symptom questionnaire. All patients underwent gastroduodenal manometry (GDM); select patients also underwent further testing including esophageal manometry (EM), anorectal manometry (ARM), plain abdominal radiography (AXR), abdominal computed tomography (CT), gastric emptying studies (GES), and colonic transit time (CTT) studies. RESULTS: The four most common symptoms were bloating, constipation, abdominal pain, and nausea/vomiting, all experienced by greater than 70 % of patients. On GDM testing, 93 % of patients demonstrated signs of neuropathy, and the most common abnormalities observed included bursts of uncoordinated phasic activity in both fasting (59 %) and post-prandial (42 %) states, low contractility in the post-prandial state (67 %), and lack of post-prandial pattern (42 %). A total of 67 % of patients undergoing EM and 86 % of those undergoing ARM demonstrated abnormalities consistent with dysmotility. On AXR or CT, 58 % demonstrated either dilated intestinal loops or air-fluid levels. On CTT 80 % demonstrated delayed colonic transit, while on GES 60 % demonstrated delayed gastric emptying. CONCLUSIONS: In this cohort of POTS patients with gastrointestinal symptoms, there is a high prevalence of abnormal manometric and radiographic findings suggestive of dysmotility.
Asunto(s)
Motilidad Gastrointestinal/fisiología , Manometría/métodos , Síndrome de Taquicardia Postural Ortostática/patología , Adolescente , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
OBJECTIVE: Cardiovascular disease is the leading cause of mortality in women in the United States. Aggressive treatment of modifiable risk factors (e.g., hypercholesterolemia) is essential in reducing disease burden. Despite guidelines recommending the use of statin treatment in hypercholesterolemic women, this patient group is often undertreated. This subgroup analysis of the Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) trial examines the effects of statin therapy in hypercholesterolemic women. METHODS: As part of the STELLAR trial, 1,146 women with elevated low-density lipoprotein cholesterol (LDL-C ≥160 and <250 mg/dL) and triglycerides <400 mg/dL were randomized to rosuvastatin 10-40 mg, atorvastatin 10-80 mg, simvastatin 10-80 mg, or pravastatin 10-40 mg for 6 weeks. RESULTS: LDL-C reduction with rosuvastatin 10 mg, atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 40 mg was 49%, 39%, 37%, and 30%, respectively, after 6 weeks. High-intensity statins (rosuvastatin 20-40 mg and atorvastatin 40-80 mg) reduced LDL-C to the greatest extent: 53% with rosuvastatin 20 mg, 57% with rosuvastatin 40 mg, 47% with atorvastatin 40 mg, and 51% with atorvastatin 80 mg. Similar results were observed for non-high-density lipoprotein cholesterol (non-HDL-C). Increases in HDL-C were greater with rosuvastatin across doses than with other statins. All treatments were well tolerated, with similar safety profiles across dose ranges. CONCLUSIONS: Statin therapies in the STELLAR trial led to reductions in LDL-C, non-HDL-C, and triglycerides and increases in HDL-C among hypercholesterolemic women, with rosuvastatin providing the greatest reductions in LDL-C and non-HDL-C.
Asunto(s)
HDL-Colesterol/efectos de los fármacos , LDL-Colesterol/efectos de los fármacos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Hipercolesterolemia/tratamiento farmacológico , Adulto , Anciano , Atorvastatina , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Femenino , Humanos , Persona de Mediana Edad , Pravastatina/orina , Rosuvastatina Cálcica/uso terapéutico , Simvastatina/uso terapéutico , Resultado del Tratamiento , Triglicéridos/uso terapéutico , Estados UnidosRESUMEN
BACKGROUND: Identification of silent atrial fibrillation (AF) could prevent stroke and other sequelae. HYPOTHESIS: Screening for AF using continuous ambulatory electrocardiographic (ECG) monitoring can detect silent AF in asymptomatic in patients with known risk factors. METHODS: We performed a single-center prospective screening study using a wearable patch-based device that provides up to 2 weeks of continuous ambulatory ECG monitoring (iRhythm Technologies, Inc.). Inclusion criteria were age ≥55 years and ≥2 of the following risk factors: coronary disease, heart failure, hypertension, diabetes, sleep apnea. We excluded patients with prior AF, stroke, transient ischemic attack, implantable pacemaker or defibrillator, or with palpitations or syncope in the prior year. RESULTS: Out of 75 subjects (all male, age 69 ± 8.0 years; ejection fraction 57% ± 8.7%), AF was detected in 4 subjects (5.3%; AF burden 28% ± 48%). Atrial tachycardia (AT) was present in 67% (≥4 beats), 44% (≥8 beats), and 6.7% (≥60 seconds) of subjects. The combined diagnostic yield of sustained AT/AF was 11%. In subjects without sustained AT/AF, 11 (16%) had ≥30 supraventricular ectopic complexes per hour. CONCLUSIONS: Outpatient extended ECG screening for asymptomatic AF is feasible, with AF identified in 1 in 20 subjects and sustained AT/AF identified in 1 in 9 subjects, respectively. We also found a high prevalence of asymptomatic AT and frequent supraventricular ectopic complexes, which may be relevant to development of AF or stroke. If confirmed in a larger study, primary screening for AF could have a significant impact on public health.
Asunto(s)
Fibrilación Atrial/diagnóstico , Electrocardiografía Ambulatoria/métodos , Tamizaje Masivo/métodos , Anciano , Enfermedades Asintomáticas , Estudios de Factibilidad , Humanos , Masculino , Persona de Mediana Edad , Pacientes Ambulatorios , Estudios Prospectivos , Accidente Cerebrovascular/prevención & controlRESUMEN
Epidemiologic evidence shows that elevated serum cholesterol, specifically low-density lipoprotein cholesterol (LDL-C), increases the risk of coronary heart disease (CHD). Moreover, large-scale intervention trials demonstrate that treatment with HMG-CoA reductase inhibitors (statins), the most effective drug class for lowering LDL-C, significantly reduces the risk of CHD events. Unfortunately, only a moderate percentage of hypercholesterolemic patients are achieving LDL-C targets specified by the National Cholesterol Education Program (NCEP), in part because clinicians are not effectively titrating medications as needed to achieve LDL-C goals. Recent evidence suggests that more aggressive LDL-C lowering may provide greater clinical benefit, even in individuals with moderately elevated serum cholesterol levels. Furthermore, recent studies suggest that statins have cardioprotective effects in many high-risk individuals, including those with baseline LDL-C <100 mg/dl. High-density lipoprotein cholesterol (HDL-C) was recognized by the NCEP-Adult Treatment Panel II (ATP II) as a negative risk factor for CHD. The NCEP-ATP III guidelines have also reaffirmed the importance of HDL-C by increasing the low HDL-C designation from <35 to <40 mg/dl as a major risk factor for CHD. Similarly, triglyceride control will play a larger role in dyslipidemia management. As more clinicians effectively treat adverse lipid and lipoprotein cardiovascular risk factors, patients will likely benefit from reductions in cardiovascular events.
Asunto(s)
Enfermedad Coronaria/prevención & control , Hiperlipidemias/terapia , Lípidos/sangre , LDL-Colesterol/sangre , Enfermedad Coronaria/sangre , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Factores de Riesgo , Triglicéridos/sangreRESUMEN
BACKGROUND: Although inducible ventricular fibrillation (VF) has been used as an indication for prophylactic implantation of cardioverter-defibrillators (ICDs) in patients with coronary artery disease (CAD), the significance of inducible VF remains controversial. METHODS: Among 364 CAD patients who underwent electrophysiologic (EP) study for risk stratification, 23 patients, 12 without any history of VF or cardiac arrest (group A) and 11 with previously documented VF or cardiac arrest (group B), exhibited inducible ventricular flutter (VFL) or VF and subsequently underwent ICD implantation. Additionally, 11 CAD patients without previous VF or cardiac arrest, who had no inducible ventricular tachyarrhythmias but received an ICD, were included for comparison (group C). RESULTS: During 2 years of follow-up, 1 (8%), 5 (45%), and 1 (9%) patients had appropriate ICD shocks in groups A, B, and C, respectively. The survival free from appropriate ICD shocks was significantly lower in group B compared to groups A and C (p<0.05). There were no significant differences in age, sex, ejection fraction (EF), or induction protocol between groups A and B or between groups A and C. CONCLUSIONS: In CAD patients with inducible VFL/VF, patients without any history of VF or cardiac arrest had significantly lower incidence of appropriate ICD shocks when compared to those with such clinical events. Conversely, in CAD patients without any history of VF or cardiac arrest, incidence of appropriate ICD shocks was similar regardless of inducible VFL/VF. Inducible VFL/VF is therefore not useful as an indication for prophylactic ICD implantation in this patient population.
Asunto(s)
Enfermedad de la Arteria Coronaria/complicaciones , Fibrilación Ventricular/etiología , Anciano , Enfermedad de la Arteria Coronaria/prevención & control , Enfermedad de la Arteria Coronaria/terapia , Desfibriladores Implantables , Técnicas Electrofisiológicas Cardíacas , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Fibrilación Ventricular/terapiaRESUMEN
BACKGROUND: Many patients who are candidates for implantable cardioverter defibrillators (ICDs) are not referred for potential implantation. We sought to determine if a simple provider reminder would increase referrals. METHODS AND RESULTS: We identified consecutive patients from January 2007 through July 2010 in the VA Palo Alto Health Care System with a left ventricular ejection fraction<35% on echocardiography. Patients were excluded using available administrative data only (no chart review) if they were known to have an ICD, if they were ≥80 years old, or if they did not have a current primary care or cardiology provider within the system. We randomized patients to no intervention or a clinical note to the provider in the medical record. The outcomes were referral for consideration of defibrillator implantation (primary) and documented discussion (secondary). Of 330 patients with left ventricular ejection fraction≤35%, 128 were known to have an ICD, 85 were no longer followed in the healthcare system, and 28 were ≥80 years old, leaving 89 patients to be randomized. Forty-six patients were randomized to intervention and 43 to control. Eleven of 46 (24%) intervention patients were referred for consideration of ICD implantation during the following 6 months versus 1 of 43 (2%) control patients (P=0.004). Overall, 31 of 46 (67%) intervention patients versus 19 of 43 (44%) control patients had documentation discussing potential candidacy for defibrillators (P=0.05). CONCLUSIONS: In patients with low left ventricular ejection fraction, a simple electronic medical record-based intervention directed to their providers improved the rates of referral for ICD implantation. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01217827.
Asunto(s)
Desfibriladores Implantables , Personal de Salud , Insuficiencia Cardíaca/terapia , Derivación y Consulta , Sistemas Recordatorios/estadística & datos numéricos , Volumen Sistólico/fisiología , Disfunción Ventricular Izquierda/fisiopatología , Factores de Edad , Anciano , Anciano de 80 o más Años , Muerte Súbita Cardíaca/prevención & control , Ecocardiografía , Femenino , Adhesión a Directriz , Insuficiencia Cardíaca/diagnóstico por imagen , Insuficiencia Cardíaca/fisiopatología , Humanos , Masculino , Sistemas de Registros Médicos Computarizados , Persona de Mediana Edad , Selección de Paciente , Estudios Retrospectivos , Resultado del Tratamiento , Disfunción Ventricular Izquierda/diagnóstico por imagenAsunto(s)
Síndrome de Taquicardia Postural Ortostática , Síncope Vasovagal , Taquicardia Sinusal , Niño , Femenino , Humanos , Masculino , Persona de Mediana Edad , Síndrome de Taquicardia Postural Ortostática/diagnóstico , Síndrome de Taquicardia Postural Ortostática/terapia , Sociedades Médicas , Síncope Vasovagal/diagnóstico , Síncope Vasovagal/terapia , Taquicardia Sinusal/diagnóstico , Taquicardia Sinusal/terapiaRESUMEN
A potential reduction in symptoms related to atrial fibrillation after treatment of gastroesophageal reflux disease symptoms with proton pump inhibitor therapy has been previously described. However, illustration of this relationship by combined 24-hour pH and ambulatory Holter monitoring has not been performed. We report 3 patients with symptoms of both palpitations and reflux who underwent simultaneous Holter and 24-hour ambulatory pH monitoring off of antireflux therapy. All of the patients reported a reduction in arrhythmia symptoms on proton pump inhibitor therapy. The findings from this preliminary series suggest a potential relationship between gastroesophageal reflux disease and atrial arrhythmias that might improve with antireflux therapy. Patients with documentation of both atrial arrhythmias and reflux should have a trial of aggressive acid suppressive therapy To further confirm this relationship, larger prospective studies are needed to assess whether maximal acid suppression improves arrhythmias.
Asunto(s)
Arritmias Cardíacas/epidemiología , Reflujo Gastroesofágico/epidemiología , Anciano , Comorbilidad , Electrocardiografía Ambulatoria , Inhibidores Enzimáticos/uso terapéutico , Esófago/química , Femenino , Reflujo Gastroesofágico/tratamiento farmacológico , Reflujo Gastroesofágico/cirugía , Humanos , Concentración de Iones de Hidrógeno , Modelos Lineales , Masculino , Persona de Mediana Edad , Monitoreo Ambulatorio , Omeprazol/uso terapéuticoRESUMEN
Individuals with abnormal blood lipids and lipoproteins are at increased risk for cardiovascular disease. With the development of effective dietary, behavioral, and pharmaceutical treatments to optimize blood lipoproteins, accurate clinical assessment of blood lipids and lipoproteins are essential for patient management and research. This article discusses the use of a variety of lipid analyses currently available. The use of traditional lipoprotein measurements, including Friedewald calculation of low-density lipoprotein (LDL) cholesterol and ultracentrifugation methods to measure blood lipoproteins, are discussed. Newer analytic techniques, including the vertical analytic profile, nuclear magnetic resonance, direct LDL measurement, LDL size determination, and triglyceride-rich lipoprotein remnants, are also described. Despite the development of a number of lipid and lipoprotein assays, lipoprotein analysis with a Friedewald- calculated LDL measurement remains the lipoprotein analysis performed in approximately 93% of clinical laboratories. It remains to be determined if the alternative lipid and lipoprotein assays currently available will become more widely utilized in the future.
Asunto(s)
Análisis Químico de la Sangre/métodos , HDL-Colesterol/análisis , LDL-Colesterol/análisis , Hiperlipidemias/diagnóstico , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Femenino , Humanos , Imagen por Resonancia Magnética/métodos , Masculino , Sensibilidad y Especificidad , Ultracentrifugación/métodosRESUMEN
To evaluate the significance of inducible sustained ventricular tachycardia (VT) in patients with coronary artery disease and relatively preserved cardiac function, 33 patients who met the following criteria were studied; documented nonsustained VT but no history of life-threatening arrhythmia, inducible sustained VT at electrophysiologic study, and implantation of a cardioverter-defibrillator. Eighteen patients developed clinical sustained VT within 2 years. By univariate analysis, left ventricular ejection fraction (EF) and the cycle length of induced VT were associated with clinical VT occurrence. By multivariate analysis, however, EF was the only independent predictor. Among 23 patients with EF
Asunto(s)
Volumen Sistólico/fisiología , Taquicardia Ventricular/fisiopatología , Anciano , Estimulación Cardíaca Artificial , Enfermedad de la Arteria Coronaria/complicaciones , Técnicas Electrofisiológicas Cardíacas , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Marcapaso Artificial , Probabilidad , Estudios Retrospectivos , Taquicardia Ventricular/etiología , Taquicardia Ventricular/terapiaRESUMEN
INTRODUCTION: Although unidirectional conduction block at the cavotricuspid isthmus can be created by radiofrequency ablation for atrial flutter, its underlying mechanism has not been elucidated. METHODS AND RESULTS: Twenty-seven patients (22 men and 5 women; mean age 59 +/- 11 years) who met the following criteria were studied: (1) bidirectional isthmus conduction demonstrable at baseline; (2) at least one linear lesion attempted on the cavotricuspid isthmus with radiofrequency catheter ablation; and (3) conduction times at anterolateral and posteromedial portions of the isthmus measured for both clockwise and counterclockwise directions before the ablation procedure. Unidirectional conduction block was observed before achieving bidirectional block in 9 patients (group I); the remaining 18 patients did not exhibit unidirectional conduction block (group II). All unidirectional conduction blocks were demonstrated in the counterclockwise direction. Anterolateral isthmus conduction time in group I was significantly longer than that in group II in both directions. However, there were no significant differences in posteromedial isthmus conduction time between groups I and II in either direction. Anterolateral isthmus conduction time was significantly longer than posteromedial conduction time in group I but not in group II. CONCLUSION: There were significant differences in conduction properties at the cavotricuspid isthmus between patients who developed unidirectional conduction block and those who did not. Our results support the notion that anisotropy contributes to the genesis of unidirectional conduction block at the cavotricuspid isthmus during the radiofrequency ablation procedure.